Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer

被引:12
|
作者
Wassermann J. [1 ,2 ]
Rosenberg S.M. [1 ,3 ]
机构
[1] Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, 02115, MA
[2] INSERM, UMR_S 1136, Paris
[3] Harvard Medical School, Boston, MA
基金
美国医疗保健研究与质量局;
关键词
Aromatase inhibitors; Breast neoplasms; Decision-making; Medication adherence; Patient compliance; Selective estrogen receptor modulators;
D O I
10.1007/s12609-017-0248-5
中图分类号
学科分类号
摘要
Purpose of Review: Treatment decisions regarding adjuvant endocrine therapy in breast cancer has become increasingly complex, with non-adherence to treatment one of the most crucial issues. We aimed to review the literature on both aspects focusing on new finding regarding assessment, determinants, and interventions of decision-making and adherence to adjuvant endocrine therapy. Recent Findings: A shared decision-making process is wanted by the patients and can improve patient-related outcomes. Information needs, preferences, and values regarding adjuvant endocrine therapy vary widely. Nearly two-thirds of patients do not take the adjuvant endocrine therapy exactly as prescribed either by not initiating, missing doses, or stopping the treatment early. Summary: Implementation of tools for a shared decision can be useful in clinical practice, but further development is needed in the field of adjuvant endocrine therapy. Targeted interventions are desirable to improve patients’ adherence to adjuvant endocrine therapy, thereby improving the quality of care and outcomes in breast cancer. © 2017, Springer Science+Business Media New York.
引用
收藏
页码:100 / 110
页数:10
相关论文
共 50 条
  • [41] Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment
    Naoki Niikura
    Morihiko Kimura
    Takayuki Iwamoto
    Naoki Hayashi
    Junichi Shintoku
    Yuki Saito
    Yasuhiro Suzuki
    Yutaka Tokuda
    Breast Cancer, 2013, 20 : 67 - 74
  • [42] ADJUVANT AND NEOADJUVANT TREATMENT OF BREAST-CANCER WITH CHEMOTHERAPY AND OR ENDOCRINE THERAPY
    BONADONNA, G
    VALAGUSSA, P
    BRAMBILLA, C
    MOLITERNI, A
    ZAMBETTI, M
    FERRARI, L
    SEMINARS IN ONCOLOGY, 1991, 18 (06) : 515 - 524
  • [43] Women Prefer Adjuvant Endocrine Therapy to Chemotherapy for Breast Cancer Treatment
    Niikura, N.
    Kimura, M.
    Iwamoto, T.
    Hayashi, N.
    Shintoku, J.
    Saito, Y.
    Suzuki, Y.
    Tokuda, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S268 - S269
  • [44] Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment
    Niikura, Naoki
    Kimura, Morihiko
    Iwamoto, Takayuki
    Hayashi, Naoki
    Shintoku, Junichi
    Saito, Yuki
    Suzuki, Yasuhiro
    Tokuda, Yutaka
    BREAST CANCER, 2013, 20 (01) : 67 - 74
  • [45] Endocrine Adjuvant Therapy for Localized Breast Cancer
    Lippman, Marc E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (02): : 193 - 194
  • [46] Status of adjuvant endocrine therapy for breast cancer
    Schiavon, Gaia
    Smith, Ian E.
    BREAST CANCER RESEARCH, 2014, 16 (02)
  • [47] ENDOCRINE ADJUVANT THERAPY FOR BREAST-CANCER
    GOLDHIRSCH, A
    GELBER, RD
    TATTERSALL, MNH
    RUDENSTAM, CM
    CAVALLI, F
    LANCET, 1985, 1 (8440): : 1274 - 1274
  • [48] Adjuvant endocrine therapy in postmenopausal breast cancer
    Ingle, JN
    CLINICAL CANCER RESEARCH, 2003, 9 (01) : 480S - 485S
  • [49] Selecting adjuvant endocrine therapy for breast cancer
    Eneman, Jonathan D.
    Wood, Marie E.
    Muss, Hyman B.
    ONCOLOGY-NEW YORK, 2004, 18 (14): : 1733 - 1744
  • [50] ENDOCRINE ADJUVANT THERAPY IN BREAST-CANCER
    STOLL, BA
    BRITISH MEDICAL JOURNAL, 1976, 2 (6043): : 1075 - 1075